[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-hypertension-due-to-lung-diseases-and-hypoxia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-hypertension-due-to-lung-diseases-and-hypoxia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,69,104,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053835","phase-2-lam-001-for-the-treatment-of-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100053835",false,"NCT05798923","LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","Inclusion Criteria:\n\n1. Age 18-80 years (\\>70 y\u002Fo requires medical monitor approval)\n2. Diagnosis of PH-ILD as defined by CT imaging within 1 year of screening that demonstrates diffuse parenchymal lung disease or abnormal PFTs (see IC #3) associated with one of the following:\n\n   1. Idiopathic interstitial pneumonia (IIP) including:\n\n      * Idiopathic pulmonary fibrosis (IPF)\n      * Idiopathic nonspecific interstitial pneumonia\n      * Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)\n      * Unclassifiable idiopathic interstitial pneumonia\n   2. Chronic hypersensitivity pneumonitis (CHP)\n   3. CTD ILD patients with lung disease findings of \\\u003C65% predicted FVC in the setting of diagnosed Connective Tissue Disease\n3. Pulmonary function tests within 6 months prior to Screening as follows:\n\n   * Forced vital capacity (FVC \\\u003C65% predicted and a DLCO \\>30) for patients with confirmatory high- resolution computed tomography (CT) indicating fibrotic lung disease\n   * For subjects with a history of lobectomy or pneumonectomy, and for whom there are no population- based normalization methods, assessment based on residual lung volume will be permitted to assess eligibility.\n4. Hemodynamics consistent with a diagnosis of precapillary PH (mPAP \\> 25 mmHg, PCWP \\\u003C 15 mmHg, PVR \\> 4.0 WU)\n5. Symptomatic pulmonary hypertension classified as WHO Functional Class II or III\n6. 6MWD ≥ 100 and ≤ 450 meters repeated twice during Screening Period and both values within 15% of each other, calculated from the highest value.\n7. On a standard of care PH therapy at stable (per SOC) dose levels for at least 90 days prior to screening.\n\n   * Stable dose is defined as no change in dose\n   * CTD ILD patients are not required to be on SOC ILD therapy but if they are, must be a stable dose for 90 days\n8. Females of childbearing potential must satisfy following:\n\n   * Have 2 negative pregnancy tests as verified by the investigator prior to starting study and must agree to ongoing pregnancy testing during the study and at end of study treatment.\n   * If sexually active, must have used, and agree to continue to use, highly effective contraception without interruption, for at least 30 days prior to starting investigational product (IP), during the study (including dose interruptions), and for 90 days after discontinuation of study treatment.\n   * Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 90 days after the last dose of study treatment.\n9. Male participants must:\n\n   * Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made from natural (animal) membrane (for example, polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 90 days following IP discontinuation, even if he has undergone a successful vasectomy.\n   * Refrain from donating sperm for the duration of the study and for 90 days after the last dose of study treatment.\n10. Ability to adhere to the study visit schedule and understand and comply with all protocol requirements.\n11. Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n1. Clinical and\u002For radiologic evidence of moderate to severe emphysema\n2. Clinical diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), supported by imaging study (e.g. ventilation-perfusion (VQ) scan, CT pulmonary angiogram (CTPA) or pulmonary angiography with findings that establish CTEPH. In the absence of a clinical diagnosis of CTEPH, an imaging study is not required.\n3. Received IV inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to Week 0 Visit\n4. History of more than moderate obstructive sleep apnea that is untreated\n5. Prior exposure to oral sirolimus or any other mTOR inhibitor within the last 90 days\n6. Smoking, vaping or e-cigarette use within 90 days of Week 0 visit\n7. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to Week 0 Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)\n8. Uncontrolled systemic hypertension as evidenced by sitting systolic BP \\> 170 mmHg or sitting diastolic BP \\> 100 mmHg during Screening Visit after a period of rest\n9. Systolic BP \\\u003C 90 mmHg during Screening Visit or at baseline\n10. History of known pericardial constriction\n11. RHC contraindicated during the study per investigator\n12. Personal or family history of long QTc syndrome or sudden cardiac death\n13. Cerebrovascular accident within 90 days of the Week 0 Visit\n14. History of restrictive or constrictive cardiomyopathy\n15. Left ventricular ejection fraction \\\u003C 45% on echocardiogram performed within 6 months prior to Screening Period (or done as a part of the Screening Period)\n16. Any current symptomatic coronary disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain in the past 6 months prior to Screening Visit).\n17. Known diagnosis (as determined by echocardiography) of significant (≥ 2+ regurgitation) mitral valve regurgitation or aortic regurgitation valvular disease\n18. Any of the following clinical laboratory values during the Screening Period prior to Week 0 Visit:\n\n    * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \\> 3x upper limit of normal (ULN) or total bilirubin \\> 1.5 x ULN within 28 days of Week 0 Visit\n    * Estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2 (4-variable Modification of Diet in Renal Disease equation) within 28 days of Week 0 Visit or required renal replacement therapy within 90 days\n19. History of opportunistic infection (e.g., invasive candidiasis or Pneumocystis pneumonia) within 6 months prior to Screening; serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to Screening\n20. History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or lactose excipients in IP\n21. Major surgery within 8 weeks prior to Week 0 Visit. Participants must have completely recovered from any previous surgery prior to Week 0 Visit\n22. Prior heart or heart-lung transplants\n23. Life expectancy of \\\u003C 12 months (per PI determination)\n24. Pregnant or breastfeeding females\n25. At any time in the 30 days prior to the Screening Period received \\> 20 mg\u002Fday of prednisone (or equivalent) or started or changed the dose of a systemic corticosteroid. Participants receiving stable doses of ≤ 20 mg prednisone (or equivalent) in 30 days prior to the Screening Period are permitted in the study.\n26. History of active malignancy within the past 5 years, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the skin\n27. History of clinically significant (as determined by the investigator) non-PH related cardiac, endocrine, hematologic, hepatic, immune, metabolic, urologic, pulmonary, neurologic, neuromuscular, dermatologic, psychiatric, renal, and\u002For other disease that may limit participation in the study\n28. Participation in another clinical trial involving intervention with another investigational drug or approved therapy for investigational use within 4 weeks prior to Week 0 Visit, or if the half-life of the previous product is known, within 5x the half-life prior to Week 0 Visit, whichever is longer\n29. Participation in another clinical trial involving an investigational device within 4 weeks prior to Week 0 Visit\n30. Any recreational drug use (cocaine, marijuana, etc.) within 90 days\n31. Unwillingness or inability to comply with the protocol- required procedures","ALL","18 Years","80 Years",{"count":20,"type":21},85,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).",[27],"Pulmonary Hypertension Due to Lung Diseases and Hypoxia",[29],"Interstitial Lung Disease","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2023-08-30",{"date":38,"type":21},"2028-08-30",{"name":40,"class":41},"OrphAI Therapeutics","INDUSTRY",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100545937","decipher-ild-a-real-world-patient-registry-in-group-3-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100545937","NCT06388421","DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to:\n\n   1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis\n   2. Autoimmune ILD\n   3. Chronic hypersensitivity pneumonitis\n   4. Nonspecific interstitial pneumonia\n   5. Occupational lung disease\n   6. Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator\n3. For patients to be eligible for Cohorts 1 to 3: RHC confirmed PH (mean pulmonary artery pressure \\>20 mmHg, pulmonary artery wedge pressure\n\n   ≤15 mmHg, pulmonary vascular resistance \\>2 WU).\n4. For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline.\n5. For patients to be eligible for Cohort 2, they must have initiated\n\nTyvaso\u002FTyvaso DPI at 1 of the following time points:\n\n1. Baseline\n2. ≤90 days prior to Baseline 6. For patients to be eligible for Cohort 3, they must be receiving Tyvaso\u002FTyvaso DPI at Baseline and for \\>90 days prior to Baseline. 7. For patients to be eligible for Cohort 4: Prior RHC not meeting the definition of PH as described in Inclusion Criterion 3 but has a pulmonary artery wedge pressure ≤15 mmHg. 8. Co-enrollment in other observational or interventional studies is permitted. 9. Patient is willing and able to provide informed consent and complete surveys\u002Fquestionnaires in English or Spanish.\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of Group 1, 2, 4, or 5 PH\n\n   a. In cases in which a patient has a diagnosis of PH-ILD along with a concomitant diagnosis of another PH group (eg, Group 1), enrollment may be permitted at the Investigator's discretion if, in their clinical judgment, PH-ILD is the predominant driver of the patient's PH.\n2. Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.\n3. Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.",{"count":50,"type":21},900,"OBSERVATIONAL","This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).",[27,54,29],"Pulmonary Hypertension",[56,57,58],"pulmonary hypertension","interstitial lung disease","pulmonary hypertension associated with interstitial lung disease","2026-06-08",{"date":61,"type":34},"2026-06-10",{"date":63,"type":34},"2025-01-23",{"date":65,"type":21},"2030-11-30",{"name":67,"class":41},"United Therapeutics",67,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100555503","ventilator-pressure-and-optimization-of-compliance-and-hemodynamics-100555503","NCT06512935","Ventilator Pressure and Optimization of Compliance and Hemodynamics","Ventilator Pressure and Optimization of Compliance and Hemodynamics: VPOCH Trial","VPOCH","Inclusion Criteria:\n\nPreterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age \\\u003C 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV.\n\n* Post-natal age \\> 7 days and less than 1 month (outside golden week protocol)\n* Gestational age ≥ 21 weeks and ≤ 34 week\n* Infants with written informed consent obtained from legal guardian\n\nExclusion Criteria:\n\n* Blood culture-positive sepsis\n* Congenital anomalies affecting respiration\n* Cyanotic or ductal-dependent congenital heart disease\n* Newborns who are considered too unstable for study enrolment per neonatology attending\n* Newborns on pressors or steroids for maintaining cardiac output\n* Non-invasive ventilation or newborn with significant BPD (bronchopulmonary dysplasia) with pulmonary hypertension (HTN)\n* Open skin wounds or abrasions on the chest wall.","7 Days","30 Days",{"count":80,"type":21},24,[82],"NA","In preterm infants \\\u003C 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants.\n\nInfants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline to determine compliance, oxygenation, and cardiac hemodynamics at each step using echocardiography (ECHO) and EIT measurements. There will be a 15-minute washout period after changes prior to data collection.",[85,27,86,87,88],"Bronchopulmonary Dysplasia","Extreme Prematurity","Ventilator Lung; Newborn","Ventilation Perfusion Mismatch",[90,91,92],"Respiratory distress syndrome","ventilation mechanics in newborn","cardiac hemodynamics newborn","2026-05-06",{"date":95,"type":34},"2026-05-11",{"date":97,"type":21},"2026-08-01",{"date":99,"type":21},"2027-06-30",{"name":101,"class":102},"University of Alabama at Birmingham","OTHER",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":113,"studyType":51,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":103},"100424568","pulmonary-hypertension-biorepository-and-registry-100424568","NCT04808596","Pulmonary Hypertension Biorepository and Registry","PHBR","Inclusion Criteria:\n\n1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)\n2. The participant has a diagnosis of pulmonary hypertension confirmed by right heart catheterization\n3. Patient is ≥ 18 years of age or older\n\nExclusion Criteria:\n\n1. Participant declines to participate (living patients only)\n2. Participant is unable to provide informed consent (living patients only)",{"count":112,"type":21},300,"6 Months","Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.",[54,116,117,118,27,119,120,121,122],"Pulmonary Arterial Hypertension","Pulmonary Hypertension Due to Left Heart Disease","Pulmonary Hypertension, Primary","Pulmonary Hypertension, Primary, 4","Pulmonary Hypertension, Primary, 2","Pulmonary Hypertension, Primary, 3","Chronic Thromboembolic Pulmonary Hypertension","2025-07-29",{"date":125,"type":34},"2025-08-01",{"date":127,"type":34},"2020-08-10",{"date":129,"type":21},"2027-07-31",{"name":131,"class":102},"University of Kansas Medical Center",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":141,"studyType":51,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":103},"100398376","giessen-pulmonary-hypertension-in-lung-cancer-registry-100398376","NCT04467333","Giessen Pulmonary Hypertension in Lung Cancer Registry","PHLHR","Inclusion Criteria:\n\n* Patient with lung cancer at the University of Giessen lung Cancer Center.\n\nExclusion Criteria:\n\n\\-",{"count":140,"type":21},500,"3 Weeks","The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.",[27],"2025-03-26",{"date":146,"type":34},"2025-04-01",{"date":148,"type":34},"2020-06-29",{"date":150,"type":21},"2040-01-29",{"name":152,"class":102},"University of Giessen"]